Phase Space Research

Paylocity Holding Corporation

PCTY · Investment summary · as of 4 August 2026

Priced close to what the business has demonstrated

Portfolio decision
Pending strategy review
Price · 4 August 2026
$139.77
12-month target
$177.53 +27%
Expected return
+27.0%
Next decision point
Date not announced

Business type: Compounder · mature and structurally stable

Investment view

At $139.77, PCTY requires a 2% five-year revenue growth rate to justify its enterprise value — less than the business already delivers, at 11%.

The two axes agree in sign and are within 0.37pp of each other (growth slack +8.94pp, margin slack +8.57pp), so this is not a case where the axes disagree - but the LOAD-BEARING uncertainty is unambiguously the margin, not the growth.

The value rests on an exit multiple of 19.8x, a terminal operating margin of 21% and a 8.3% cost of capital. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.

The strongest argument against this view: Named cause: a front-end easing cycle that arrives TOGETHER WITH a softening labour market.

Underwriting bridge

QuestionEvidence-based conclusion
What drives the business?The two axes agree in sign and are within 0.37pp of each other (growth slack +8.94pp, margin slack +8.57pp), so this is not a case where the axes disagree - but the LOAD-BEARING uncertainty is unambiguously the margin, not the growth.
What do we forecast?Revenue growth of 11% demonstrated; a terminal operating margin of 21%; an exit multiple of 19.8x.
What does Street forecast?Not determined — no consensus estimates are joined to this record
Where do we differ?On terminal margin, the difference between what the price requires and what the business has demonstrated is +8.6 percentage points.
What is it worth?Twelve-month target $177.53, +27% from the struck price. Scenario-weighted expected return net of costs +27.0%.
Why now?Date not announced — no dated event that would resolve the disagreement is on file

What must go right

  1. By Date not announced — no test date is stated for this conditionRecurring revenue growth (excluding client-fund interest income) falls at or above 8.0% year-on-year for two consecutive quartersWhere it stands: Not determined — no current reading of this metric is on file
  2. By Date not announced — no test date is stated for this conditionEx-float operating margin stops expanding - i.e. falls at or above 15.0% on a TTM basisWhere it stands: Not determined — no current reading of this metric is on file
  3. By Date not announced — no test date is stated for this conditionThe condition does not occur: Average client-fund balance declines year-on-year for two consecutive quartersWhere it stands: Not determined — no current reading of this metric is on file

Catalysts and falsifiers

Date not announced — no dated event that would resolve the disagreement is on file

Risk and sell discipline

Impairment case

Named cause: a front-end easing cycle that arrives TOGETHER WITH a softening labour market. The mechanism is that Paylocity's two principal exposures are positively correlated rather than offsetting - rate cuts arrive BECAUSE employment is weakening. Falling short rates cut float income at 100% margin (-$32.3m per 100bp on the disclosed $3,230.9m floating balance, unhedged, ~84% overnight) while the same weakening labour market cuts employees-on-platform, which is the billing unit (per employee per month), and lengthens mid-market sales cycles, which is where the ~7% new-logo engine lives. A second, independent cause: competitive displacement in mid-market HCM, where Paycom, Dayforce, Rippling and Gusto all attack the same 50-1,000-employee band and switching costs are real but not absolute.

Estimated probability 25%, against the 29% level at which the position would be resized. It sits within that level.

Fundamental invalidation

Falsifiable and fundamental — not one of them is a price condition.

Price-based risk trigger

A daily close below $120.69 triggers an immediate review of the thesis and pauses additional buying. It is not an automatic sell unless a separate fundamental invalidation condition has been breached.

Upside sell discipline

Trim or exit on valuation and opportunity cost when the forward 12-month expected return falls below the hurdle of E[R] > 0 net of costs, assessed against the ranked book rather than in isolation. On approach to the $177.53 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default. The position is trimmed once forward expected return falls below 0% net of costs, because the capital has a better use elsewhere in the book.

Investment criteria

CriteriaStatusInvestment meaning
QualityMetIs the business worth owning under its declared economic type?
ValuationMetIs the operating path required by today's price achievable?
LiquidityMetCan the intended position be built and exited in the right vehicle?
DownsideMetNamed cause: a front-end easing cycle that arrives TOGETHER WITH a softening labour market.
MomentumNot determinedDoes price action support or complicate entry timing? Not established on the evidence on file.
CatalystNot determinedIs there a dated event that resolves the disagreement? Not established on the evidence on file.
ConsensusNot determinedIs the house-versus-Street disagreement identified and quantified? Not established on the evidence on file.

Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.

Bottom line

The strongest case for mispricing is that the business already delivers +8.6 percentage points more growth than the price requires. The most important unresolved uncertainty is the permanent-loss mechanism: named cause: a front-end easing cycle that arrives TOGETHER WITH a softening labour market. The next evidence that should change the portfolio decision is the next scheduled results, or a daily close below $120.69, which forces an immediate review.